Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.

Kats LM, Vervoort SJ, Cole R, Rogers AJ, Gregory GP, Vidacs E, Li J, Nagaraja R, Yen KE, Johnstone RW.

Leukemia. 2017 Jun;31(6):1466-1470. doi: 10.1038/leu.2017.84. Epub 2017 Mar 10. No abstract available.

PMID:
28280273
2.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.

3.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project; Australian Ovarian Cancer Study Group (AOCS); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. Epub 2016 Sep 12. No abstract available.

PMID:
27617737
4.

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.

Hogg SJ, Newbold A, Vervoort SJ, Cluse LA, Martin BP, Gregory GP, Lefebure M, Vidacs E, Tothill RW, Bradner JE, Shortt J, Johnstone RW.

Mol Cancer Ther. 2016 Sep;15(9):2030-41. doi: 10.1158/1535-7163.MCT-15-0924. Epub 2016 Jul 12.

5.

Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.

Ghisi M, Kats L, Masson F, Li J, Kratina T, Vidacs E, Gilan O, Doyle MA, Newbold A, Bolden JE, Fairfax KA, de Graaf CA, Firth M, Zuber J, Dickins RA, Corcoran LM, Dawson MA, Belz GT, Johnstone RW.

Cancer Cell. 2016 Jul 11;30(1):59-74. doi: 10.1016/j.ccell.2016.05.019. Epub 2016 Jun 30.

6.

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW.

Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.

7.

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW.

Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.

8.

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.

Salmon JM, Bots M, Vidacs E, Stanley KL, Atadja P, Zuber J, Johnstone RW.

Clin Epigenetics. 2015 Jan 22;7:2. doi: 10.1186/s13148-014-0034-4. eCollection 2015.

9.

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.

Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, Lefebure M, Martin BP, Dawson MA, Johnstone RW, Shortt J.

Leukemia. 2015 Jun;29(6):1437-41. doi: 10.1038/leu.2015.10. Epub 2014 Jan 12. No abstract available.

10.

Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.

Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW.

Cell Rep. 2013 Nov 27;5(4):1047-59. doi: 10.1016/j.celrep.2013.10.038. Epub 2013 Nov 21.

11.

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

Matthews GM, Lefebure M, Doyle MA, Shortt J, Ellul J, Chesi M, Banks KM, Vidacs E, Faulkner D, Atadja P, Bergsagel PL, Johnstone RW.

Cell Death Dis. 2013 Sep 12;4:e798. doi: 10.1038/cddis.2013.306.

12.

Modulation of antitumour immune responses by intratumoural Stat1 expression.

Messina NL, Banks KM, Vidacs E, Martin BP, Long F, Christiansen AJ, Smyth MJ, Clarke CJ, Johnstone RW.

Immunol Cell Biol. 2013 Oct;91(9):556-67. doi: 10.1038/icb.2013.41. Epub 2013 Aug 20.

PMID:
23958683

Supplemental Content

Loading ...
Support Center